John Mauldin's &quo...
Health Care: Drugs
Affymax Inc. (AFFY: NASDAQ)
$14.06 -0.11 | -0.78%
05/23/12 - 10:00 AM ET
57.27K / 1.54M
Vol / Avg. Vol:14.00 / 14.17
Open / Prev. Close:13.82 - 14.20
Today's Range:3.93 - 16.25
52 Wk Range:114.37%
Performance YTD:TheStreet Rating:
Portfolios with AFFY
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserBurrdee
- ContributorStocks At New 52-Week Highs...
- Usersimulator
- Contributor10 Biotech Stocks on Clinic...
- UserPART 5 JPMorgan 28th Annual...
Latest AFFY Headlines from TheStreet
- 8 Stocks Rising on Monster Volume 04.02.12 | 01:04 pm
- Biotech Stock Mailbag: MAP Pharma, Affymax 03.30.12 | 05:03 am
- 8 Stocks Rising on Huge Volume 03.23.12 | 02:03 pm
- Biotech Stock Mailbag: Xoma's Big Backers, FDA Approvals Contest 03.23.12 | 05:03 am
- The Next Big Thing in Biotech: FDA Decisions
03.23.12 | 05:03 am - Biotech Stock Chat: Recap 03.15.12 | 11:03 am
- 5 Stocks Ready to Soar on Bullish Earnings 03.13.12 | 06:03 am
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- 6 Stocks at New 52-Week Highs 02.14.12 | 02:02 pm
Press Releases for AFFY
- Affymax Reports First Quarter 2012 Financial Results - Business Wire 05.07.12 | 04:05 pm
- Affymax And Takeda Announce Centers For Medicare And Medicaid Services Has Assigned A Q-Code For OMONTYS® (Peginesatide) Injection - Business Wire 04.13.12 | 08:04 am
- Affymax Receives A $50 Million Milestone Payment For U.S. Approval Of OMONTYS® (peginesatide) Injection - Business Wire 04.09.12 | 04:04 pm
- Affymax And Takeda Announce FDA Approval Of OMONTYS® (Peginesatide) Injection For The Treatment Of Anemia Due To Chronic Kidney Disease (CKD) In Adult Patients On Dialysis - Business Wire 03.27.12 | 02:03 pm
- Affymax® Reports Year End 2011 Financial Results - Business Wire 03.14.12 | 04:03 pm
- Affymax Announces Yearend 2011 Financial Results Teleconference And Webcast - Business Wire 03.07.12 | 04:03 pm
- Affymax To Receive $5 Million Milestone Payment For Acceptance Of European Marketing Authorization Application For Peginesatide - Business Wire 02.27.12 | 08:02 am
- Affymax Announces Upcoming Webcasts And Conference Participation - Business Wire 02.21.12 | 04:02 pm
- Affymax To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.08.12 | 04:02 pm
- Affymax Promotes Cynthia Smith To Vice President, Market Access And Commercial Development - Business Wire 02.02.12 | 04:02 pm
Partner Headlines for AFFY
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 05.23.12 | 09:05 am
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Cramer's Lightning Round - Danaher Has Good Blood Lines (2/10/12) - Seeking Alpha 02.12.12 | 07:02 am
- Affymax Spiking Higher on Heavy Volume - Benzinga 12.27.11 | 01:12 pm
- 7 Stocks With Unusual Options Activity - Seeking Alpha 12.09.11 | 09:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Company News for December 6, 2011 - Corporate Summary - Zacks 12.06.11 | 10:12 am
